Protagenic Therapeutics exchanges 459,420 warrants for 367,544 shares at 0.8 ratio

Protagenic Therapeutics, Inc.new

Warrant Exchange Agreement with unaffiliated holder to cancel 459,420 warrants for 367,544 common shares.
Exchange relies on Section 3(a)(9) exemption; shares issued without restrictive legends.
Transaction to be completed within six months of May 20, 2025.
Net reduction of 91,876 potential shares outstanding compared to exercise of warrants.

item 1.01item 3.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.